Literature DB >> 18063128

Implementation of an intensified infection control program to reduce MRSA transmissions in a German tertiary care hospital.

Matthias Trautmann1, Angela Pollitt, Ulrike Loh, Iris Synowzik, Wolfgang Reiter, Jens Stecher, Michael Rohs, Ulrich May, Elisabeth Meyer.   

Abstract

BACKGROUND: Germany has witnessed increasing national methicillin-resistant Staphylococcus aureus (MRSA) rates during the past 2 decades. In our 900-bed tertiary care community hospital, a similar increase was noted during the period from 1994 to 2002, although single-room isolation and decolonization therapy were the standard of care.
METHODS: An intensified infection control program aimed at the reduction of nosocomial MRSA transmissions was developed in 2002 and translated into clinical practice in 2003. Essential components of the program were a detailed written MRSA standard, acquisition of signal-colored isolation gowns and storage carts facilitating the use of separate supplies for MRSA patients, intensified surveillance and feedback of MRSA data, "flagging" of formerly positive MRSA patients, and a general MRSA screening policy for all newly admitted patients on the surgical intensive care unit (ICU). The effect of the program was monitored by continuous surveillance of MRSA cases on all wards. The transmission index was defined as the ratio between secondary and "imported" MRSA cases.
RESULTS: Comparing the preintervention (2002) and postintervention (2005-2006) periods, the total number of MRSA patients, MRSA rates on the ICUs, and invasive MRSA infections on the ICUs were reduced. The MRSA transmission index fell from 2.1 (2002) to 0.8 (2006). The rate of deep incisional and organ/space infections due to MRSA occurring after orthopedic surgery was lowered from 0.74 to 0.15%.
CONCLUSIONS: Our data indicate that the efficacy of single-room isolation and decolonization therapy can be strongly enhanced by means of a multicomponent, comprehensive MRSA control program. The program was effective despite an increasing "import" of new MRSA cases. Programs of this type may be suited to achieve a downward turn of MRSA figures in Germany.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18063128     DOI: 10.1016/j.ajic.2007.04.280

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  6 in total

Review 1.  The epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Germany.

Authors:  Robin Köck; Alexander Mellmann; Frieder Schaumburg; Alexander W Friedrich; Frank Kipp; Karsten Becker
Journal:  Dtsch Arztebl Int       Date:  2011-11-04       Impact factor: 5.594

2.  Impact of a change in antibiotic prophylaxis on total antibiotic use in a surgical intensive care unit.

Authors:  E Meyer; F Schwab; A Pollitt; W Bettolo; B Schroeren-Boersch; M Trautmann
Journal:  Infection       Date:  2009-11-10       Impact factor: 3.553

3.  Epidemiology of MRSA and current strategies in Europe and Japan.

Authors:  Axel Kramer; Hans Wagenvoort; Christina Ahrén; Inka Daniels-Haardt; Philippe Hartemann; Hiro Kobayashi; Andrea Kurcz; Juan Picazo; Gaetano Privitera; Ojan Assadian
Journal:  GMS Krankenhhyg Interdiszip       Date:  2010-02-10

4.  Implementing the MRSA recommendations made by the Commission for Hospital Hygiene and Infection Prevention (KRINKO) of 1999 - current considerations by the DGKH Management Board.

Authors:  Arne Simon; Martin Exner; Axel Kramer; Steffen Engelhart
Journal:  GMS Krankenhhyg Interdiszip       Date:  2009-04-09

5.  Long-term persistence of MRSA in re-admitted patients.

Authors:  F Mattner; F Biertz; S Ziesing; P Gastmeier; I F Chaberny
Journal:  Infection       Date:  2010-07-03       Impact factor: 3.553

6.  Successful reduction of hospital-acquired methicillin-resistant Staphylococcus aureus in a urology ward: a 10-year study.

Authors:  Manabu Tatokoro; Kazunori Kihara; Hitoshi Masuda; Masaya Ito; Soichiro Yoshida; Toshiki Kijima; Minato Yokoyama; Kazutaka Saito; Fumitaka Koga; Satoru Kawakami; Yasuhisa Fujii
Journal:  BMC Urol       Date:  2013-07-18       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.